TELA
TELA Bio, Inc.
0.72
2 x 0.54
2 x 0.96
bid
ask
-
0.03
4.00%
2 @ 08:03 AM
0.72 +0.00 (0.00%)
| Ytd | -38.98% | |
| 1y | -63.08% |
0.72
day range
0.78
0.50
52 week range
2.20
| Open | 0.75 | Prev Close | 0.75 | Low | 0.72 | High | 0.78 | Mkt Cap | 32.23M |
| Vol | 35.88K | Avg Vol | 168.64K | EPS | -0.79 | P/E | N/A | Forward P/E | -4.31 |
| Beta | 0.97 | Short Ratio | 1.28 | Inst. Own | 51.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 0.87 | 200-d Avg | 1.02 | 1yr Est | 9.20 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.37 | -0.42 | -0.05 | -13.51% |
| 2024-08-12 | 2024-06 | -0.45 | -0.51 | -0.06 | -13.33% |
| 2024-08-12 | 2024-06 | -0.45 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.48 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.48 | -0.23 | 0.25 | 52.08% |
| 2024-03-21 | 2023-12 | -0.44 | -0.53 | -0.09 | -20.45% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-08 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-10-04 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-08-13 | Lake Street | Upgrade | Buy | Buy |
| 2024-08-13 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-08-13 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-08-13 | Piper Sandler | Upgrade | Overweight | Overweight |
Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-03 | AZARBARZIN KURT | Director | 10.52K | Stock Award(Grant) |
| 2024-06-03 | BURGESS VINCENT J | Director | 15.38K | Stock Award(Grant) |
| 2024-06-03 | COLLERAN LISA N | Director | 10.52K | Stock Award(Grant) |
| 2024-10-23 | CUCA ROBERTO | Chief Operating Officer | 155.39K | Purchase |
| 2024-06-03 | EVANS DOUGLAS G | Director | 10.52K | Stock Award(Grant) |
| 2024-10-23 | FIRESTONE GREGORY A | Officer | 57.28K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Essex Woodlands Management Inc. | 4.11M | 12.04M | 10.44% |
| 2024-09-29 | AIGH Capital Management LLC | 2.47M | 7.24M | 6.27% |
| 2024-09-29 | Orbimed Advisors LLC. | 2.16M | 6.33M | 5.49% |
| 2024-09-29 | Nantahala Capital Management, LLC | 1.92M | 5.61M | 4.86% |
| 2024-09-29 | SilverArc Capital Management, LLC | 1.12M | 3.30M | 2.86% |
| 2024-09-29 | Stonepine Capital Management, LLC | 1.11M | 3.25M | 2.82% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 643.29K | 1.88M | 1.63% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 226.80K | 664.52K | 0.58% |
| 2024-07-30 | Federated Hermes Kaufmann Fund | 153.97K | 451.13K | 0.39% |
| 2024-10-30 | Jacob Discovery Fd | 139.78K | 409.54K | 0.35% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 101.00K | 295.93K | 0.26% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 81.20K | 237.92K | 0.21% |